MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide. The ...

Pacific Biosciences of California (PACB) closed the latest trading day at $2.06, indicating a -1.9% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.47% for the day. Elsewhere, the Dow saw an upswing of 0.79%, while the tech-heavy Nasdaq appreciated by 0.28%. Shares of the maker of genetic analysis technology witnessed a gain of 12.3% over the previous month, beating the performance of the Medical sector with its loss of 4.27% and the S&P 500's gain o ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings and product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist. In the year-to-date period, this Zacks Rank #3 (Hold) company's shares have lost 79.1% against 6.6% growth of the industry. The S&P 500 composite has also gained 21.9% in the ...

Pacific Biosciences, Inc. (PACB) , popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Leveraging PacBio's Onso short-read sequencing platform, the collaboration aims to enable researchers to profile the genomic landscape of prevalent cancers, including gastrointestinal stromal tumors. PacBio's partner, Diethelm Keller Siber Hegner (DKSH), a Swiss company specializing in market expansion services, ...

文章核心观点 - 公司与新加坡国立癌症中心(NCCS)签署研究合作协议,旨在利用公司的先进测序技术,包括Onso短读测序平台和Kinnex长读测序套件,对亚洲常见癌症进行基因组学分析 [1][2][3] - 该合作项目将重点关注单细胞RNA测序,以更好地探索癌症样本中的基因组变异,为精准肿瘤诊断和治疗提供支持 [2][3] - 公司在亚洲的授权渠道合作伙伴DKSH已将Onso平台安装在NCCS的癌症发现中心,这将使新加坡以及整个亚洲地区的研究人员都能获得这项前沿技术 [3] - 公司的长读测序平台Revio与Onso短读测序的结合,将使研究人员能够进行更全面的多组学研究,深入分析肿瘤基因组 [3] 公司概况 - 公司是一家生命科学技术公司,专注于开发先进的测序解决方案,帮助科学家和临床研究人员解决复杂的遗传问题 [5] - 公司的核心技术包括HiFi长读测序和SBB短读测序,广泛应用于人类遗传、植物动物科学、传染病和肿瘤等领域 [5] 合作背景 - 公司与新加坡国立癌症中心(NCCS)签署研究合作协议,旨在利用公司的先进测序技术加速癌症研究 [1][3] - 该合作项目将重点关注亚洲常见癌症的基因组学分析 [1][2] - 公司在亚洲的授权渠道合作伙伴DKSH参与了该项目,为NCCS的癌症发现中心安装了Onso测序平台 [3] 合作目标 - 利用Onso短读测序平台检测癌症样本中的临床相关突变,为精准诊断和治疗提供支持 [2] - 结合Revio长读测序,进行更全面的多组学研究,深入分析肿瘤基因组 [3] - 该合作不仅将惠及新加坡,还将使整个亚洲地区的研究人员获得这项前沿技术 [3]

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888 ...

The most recent trading session ended with Pacific Biosciences of California (PACB) standing at $1.81, reflecting a +0.56% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.54%. At the same time, the Dow added 0.72%, and the tech-heavy Nasdaq gained 0.65%. Prior to today's trading, shares of the maker of genetic analysis technology had gained 6.51% over the past month. This has outpaced the Medical sector's gain of 4.37% and the S&P 500's ...

Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women's and Children's Hospital in Singapore. The consortium will use PACB's HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the AsiaPacific region and leverages DNAstack's federated data platform to ensure secure, global co ...

Pacific Biosciences of California, Inc. (PACB) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases. Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome's role in male infertility, and support Germany's GenomeDE Modellvorhaben project. The results will ...

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages ...